Tikvah Management LLC Purchases Shares of 2,460,833 Atyr PHARMA INC (NASDAQ:ATYR)

Tikvah Management LLC purchased a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR) in the 4th quarter, Holdings Channel reports. The fund purchased 2,460,833 shares of the company’s stock, valued at approximately $8,908,000. Atyr PHARMA accounts for about 2.5% of Tikvah Management LLC’s investment portfolio, making the stock its 15th biggest position.

Several other institutional investors have also recently made changes to their positions in ATYR. Alterna Wealth Management Inc. bought a new position in Atyr PHARMA in the fourth quarter worth approximately $36,000. Victory Capital Management Inc. purchased a new stake in shares of Atyr PHARMA in the 4th quarter worth $37,000. Raymond James Financial Inc. bought a new position in Atyr PHARMA in the 4th quarter worth $39,000. JPMorgan Chase & Co. lifted its position in Atyr PHARMA by 52.0% during the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after purchasing an additional 10,754 shares in the last quarter. Finally, ExodusPoint Capital Management LP bought a new stake in Atyr PHARMA during the fourth quarter valued at about $61,000. Institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

ATYR has been the subject of a number of recent research reports. Leerink Partners began coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price objective for the company. Leerink Partnrs upgraded shares of Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Friday, March 14th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Atyr PHARMA currently has an average rating of “Buy” and a consensus price target of $18.60.

Atyr PHARMA Price Performance

ATYR stock opened at $2.62 on Friday. The company has a market capitalization of $232.81 million, a PE ratio of -2.79 and a beta of 0.95. The company’s fifty day moving average price is $3.57 and its 200-day moving average price is $3.21. Atyr PHARMA INC has a one year low of $1.42 and a one year high of $4.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. On average, equities analysts anticipate that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.